R
Robert C. Doebele
Researcher at University of Colorado Boulder
Publications - 291
Citations - 22985
Robert C. Doebele is an academic researcher from University of Colorado Boulder. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 58, co-authored 263 publications receiving 17538 citations. Previous affiliations of Robert C. Doebele include University of Chicago & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Alexander Drilon,Theodore W. Laetsch,Shivaani Kummar,Steven G. DuBois,Ulrik Lassen,George D. Demetri,Michael J. Nathenson,Robert C. Doebele,Anna F. Farago,Alberto S. Pappo,Brian Turpin,Afshin Dowlati,Marcia S. Brose,Leo Mascarenhas,Noah Federman,Jordan Berlin,Wafik S. El-Deiry,Christina S. Baik,John F. Deeken,Valentina Boni,Ramamoorthy Nagasubramanian,Matthew H. Taylor,Erin R. Rudzinski,Funda Meric-Bernstam,Davendra Sohal,Patrick C. Ma,Luis E. Raez,Jaclyn F. Hechtman,Ryma Benayed,Marc Ladanyi,Brian B. Tuch,Kevin Ebata,Scott Cruickshank,Nora Ku,Michael C. Cox,Douglas S. Hawkins,David S. Hong,David S. Hong,David M. Hyman +38 more
TL;DR: Larotrectinib had marked and durable antitumor activity in patients with TRK fusion–positive cancer, regardless of the age of the patient or of the tumor type.
Journal ArticleDOI
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Sai-Hong Ignatius Ou,Yung-Jue Bang,D. Ross Camidge,Benjamin Solomon,Ravi Salgia,Gregory J. Riely,Marileila Varella-Garcia,Geoffrey I. Shapiro,Daniel B. Costa,Robert C. Doebele,Long P. Le,Zongli Zheng,Zongli Zheng,Weiwei Tan,Patricia Stephenson,S. Martin Shreeve,L. Tye,James G. Christensen,Keith D. Wilner,Jeffrey W. Clark,A. John Iafrate +21 more
TL;DR: Crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC, and ROS1 rearrangement defines a second molecular subgroup of NSCLCs for which crizotin ib is highly active.
Journal ArticleDOI
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele,Amanda B. Pilling,Dara L. Aisner,Tatiana G. Kutateladze,Anh T. Le,Andrew Weickhardt,Kimi L. Kondo,Derek J. Linderman,Lynn E. Heasley,Wilbur A. Franklin,Marileila Varella-Garcia,D. Ross Camidge +11 more
TL;DR: Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of separate oncogenic drivers.
Journal ArticleDOI
Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology
David S. Ettinger,Douglas E. Wood,Dara L. Aisner,Wallace Akerley,Jessica Bauman,Lucian R. Chirieac,Thomas A. D'Amico,Malcolm M. DeCamp,Thomas J. Dilling,Michael C. Dobelbower,Robert C. Doebele,Ramaswamy Govindan,Matthew A. Gubens,Mark Hennon,Leora Horn,Ritsuko Komaki,Rudy P. Lackner,Michael Lanuti,Ticiana A. Leal,Leah J. Leisch,Rogerio Lilenbaum,Jules Lin,Billy W. Loo,Renato Martins,Gregory A. Otterson,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +34 more
TL;DR: This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastasis disease.
Journal ArticleDOI
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Robert C. Doebele,Alexander Drilon,Alexander Drilon,Luis Paz-Ares,Salvatore Siena,Alice T. Shaw,Anna F. Farago,Collin M. Blakely,Takashi Seto,Byung Chul Cho,D. Tosi,Benjamin Besse,Sant P. Chawla,Lyudmila Bazhenova,John C. Krauss,Young Kwang Chae,Minal A. Barve,Ignacio Garrido-Laguna,Stephen V. Liu,Paul Conkling,Thomas John,Marwan Fakih,Darren Sigal,Herbert H. Loong,Gary L Buchschacher,Pilar Garrido,Jorge Nieva,Conor E. Steuer,Tobias Overbeck,Daniel W. Bowles,Elizabeth Fox,Todd Riehl,Edna Chow-Maneval,B. Simmons,Na Cui,Ann M. Johnson,Susan Eng,Timothy R. Wilson,George D. Demetri +38 more
TL;DR: Results show that entrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile.